DE69513395D1 - Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden - Google Patents
Zellulare abgabesystem mit cyclodextrin, für oligonukleotidenInfo
- Publication number
- DE69513395D1 DE69513395D1 DE69513395T DE69513395T DE69513395D1 DE 69513395 D1 DE69513395 D1 DE 69513395D1 DE 69513395 T DE69513395 T DE 69513395T DE 69513395 T DE69513395 T DE 69513395T DE 69513395 D1 DE69513395 D1 DE 69513395D1
- Authority
- DE
- Germany
- Prior art keywords
- cyclodextrin
- oligonucleotides
- oligonucleotide
- delivery system
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25207294A | 1994-06-01 | 1994-06-01 | |
PCT/US1995/006916 WO1995032739A1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69513395D1 true DE69513395D1 (de) | 1999-12-23 |
DE69513395T2 DE69513395T2 (de) | 2000-07-27 |
Family
ID=22954476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69513395T Expired - Fee Related DE69513395T2 (de) | 1994-06-01 | 1995-06-01 | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden |
Country Status (12)
Country | Link |
---|---|
US (3) | US5691316A (de) |
EP (1) | EP0762898B1 (de) |
JP (1) | JPH10501237A (de) |
CN (1) | CN1158088A (de) |
AT (1) | ATE186647T1 (de) |
AU (1) | AU2764395A (de) |
CA (1) | CA2191777A1 (de) |
DE (1) | DE69513395T2 (de) |
DK (1) | DK0762898T3 (de) |
ES (1) | ES2139904T3 (de) |
GR (1) | GR3032355T3 (de) |
WO (1) | WO1995032739A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099959A1 (en) * | 1995-04-12 | 2003-05-29 | Kandimalla Ekambar R. | Cooperative oligonucleotides |
US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US6573101B1 (en) * | 1998-02-12 | 2003-06-03 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
US20060199778A1 (en) * | 2001-09-19 | 2006-09-07 | Rutledge Ellis-Behnke | Methods and products related to non-viral transfection |
WO2004033620A2 (en) * | 2001-11-02 | 2004-04-22 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
EP2277551B1 (de) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
MXPA05003591A (es) * | 2002-10-09 | 2005-09-30 | Insert Therapeutics Inc | Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos. |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
ATE479752T1 (de) | 2003-03-07 | 2010-09-15 | Alnylam Pharmaceuticals Inc | Therapeutische zusammensetzungen |
US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
JP4991288B2 (ja) | 2003-04-17 | 2012-08-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 二本鎖iRNA剤、および二本鎖iRNA剤の対合の安定性を調節する方法。 |
EP2508608A1 (de) | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Verfahren zur Behandlung neurodegenerativer Erkrankungen |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
US7883688B2 (en) * | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
WO2010011895A1 (en) * | 2008-07-25 | 2010-01-28 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
WO2010017329A1 (en) * | 2008-08-06 | 2010-02-11 | Rgo Biosciences Llc | Molecular entities for binding, stabilization and cellular delivery of charged molecules |
CN102317472A (zh) * | 2008-12-12 | 2012-01-11 | 欧洲基因技术股份有限公司 | 使用环糊精改进核酸扩增反应的特异性、灵敏度和产率 |
US20100197041A1 (en) * | 2009-01-30 | 2010-08-05 | Thomas Hermann | Nucleic acid binding assays |
CN102781237A (zh) * | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
WO2011097138A1 (en) * | 2010-02-04 | 2011-08-11 | Rgo Bioscience Llc | Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
WO2012122313A2 (en) | 2011-03-08 | 2012-09-13 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
GB201216387D0 (en) | 2012-09-13 | 2012-10-31 | Ge Healthcare Uk Ltd | Solid matrix for one step nucleic acid amplification |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
KR101465365B1 (ko) * | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법 |
WO2018013999A1 (en) | 2016-07-15 | 2018-01-18 | Am Chemicals Llc | Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis |
US20190177800A1 (en) * | 2017-12-08 | 2019-06-13 | 10X Genomics, Inc. | Methods and compositions for labeling cells |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP3802819A1 (de) * | 2018-05-30 | 2021-04-14 | AXOLABS GmbH | Verfahren zum nachweis von oligonukleotidkonjugaten |
CN114874358B (zh) * | 2022-04-11 | 2023-05-02 | 上海师范大学 | 一种多核铈纳米材料的合成方法及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
PT91088B (pt) * | 1988-07-07 | 1995-01-31 | Univ Pennsylvania | Processo de preparacao de composicoes a base de alfa-,beta- ou gama- -cilcodextrinas |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
JPH05170650A (ja) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | 医薬組成物およびその製造方法 |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
-
1994
- 1994-11-17 US US08/341,522 patent/US5691316A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 ES ES95922923T patent/ES2139904T3/es not_active Expired - Lifetime
- 1995-06-01 DE DE69513395T patent/DE69513395T2/de not_active Expired - Fee Related
- 1995-06-01 DK DK95922923T patent/DK0762898T3/da active
- 1995-06-01 EP EP95922923A patent/EP0762898B1/de not_active Expired - Lifetime
- 1995-06-01 CA CA002191777A patent/CA2191777A1/en not_active Abandoned
- 1995-06-01 CN CN95194366A patent/CN1158088A/zh active Pending
- 1995-06-01 JP JP8501182A patent/JPH10501237A/ja not_active Withdrawn
- 1995-06-01 AU AU27643/95A patent/AU2764395A/en not_active Abandoned
- 1995-06-01 WO PCT/US1995/006916 patent/WO1995032739A1/en active IP Right Grant
- 1995-06-01 AT AT95922923T patent/ATE186647T1/de not_active IP Right Cessation
- 1995-06-07 US US08/480,834 patent/US5616565A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,833 patent/US5605890A/en not_active Expired - Lifetime
-
2000
- 2000-01-13 GR GR20000400052T patent/GR3032355T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5616565A (en) | 1997-04-01 |
GR3032355T3 (en) | 2000-04-27 |
EP0762898A1 (de) | 1997-03-19 |
ES2139904T3 (es) | 2000-02-16 |
WO1995032739A1 (en) | 1995-12-07 |
JPH10501237A (ja) | 1998-02-03 |
EP0762898B1 (de) | 1999-11-17 |
CN1158088A (zh) | 1997-08-27 |
DK0762898T3 (da) | 2000-04-25 |
DE69513395T2 (de) | 2000-07-27 |
AU2764395A (en) | 1995-12-21 |
US5605890A (en) | 1997-02-25 |
ATE186647T1 (de) | 1999-12-15 |
US5691316A (en) | 1997-11-25 |
CA2191777A1 (en) | 1995-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69513395D1 (de) | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden | |
ATE332918T1 (de) | Neoglycoproteine | |
ATE494010T1 (de) | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
DE69906977D1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
ATE345045T1 (de) | Desinfizierendes jod-harz, verfahren zu seiner herstellung und verwendung in textilen kombinationen | |
ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
ATE156517T1 (de) | Antisens-oligonukleotide zur behandlung von krebs | |
CY1113984T1 (el) | Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων | |
BRPI0012196B8 (pt) | artigo industrializado | |
CY1109437T1 (el) | ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ | |
CY1110590T1 (el) | Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα | |
EP1362127A4 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
MY134896A (en) | Therapeutic agent for hepatitis | |
DK0841912T3 (da) | 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning | |
PT768886E (pt) | Efeitos de revestimento endotelial e tratamento de desordens vasospasticas | |
ATE396742T1 (de) | Komplexe mit adjuvanter wirkung | |
ATE291586T1 (de) | Humanes antibiotisches protein | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
ATE317263T1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
ZA9915B (en) | Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer. | |
PL373511A1 (en) | Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use | |
HK1025558A1 (en) | Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock | |
CY1107455T1 (el) | Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |